Compound ID | 2918
Class: Small molecule antibacterial agent
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | Active against Enterococcus faecalis, Salmonella typhimurium, and uropathogenic Escherichia coli |
Description: | Synthetic compound; approved by FDA as chemotherapeutic drug for treating chronic myelogenous leukaemia; a repurposed drug; does not have an intrinsic antibacterial effect but enhances macrophage clearance of bacterial infection |
Institute where first reported: | Singapore-MIT Alliance for Research and Technology Centre, Antimicrobial Drug Resistance Interdisciplinary Research Group, 138602 Singapore |
Year first mentioned: | 2024 |
Development status: | Experimental |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/5328940 |
Guide to Pharmacology: | bosutinib |
Citation: | https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00086 |